US20080234194A1 - Growth factor mediated cosmeceuticals and use thereof to enhance skin quality - Google Patents

Growth factor mediated cosmeceuticals and use thereof to enhance skin quality Download PDF

Info

Publication number
US20080234194A1
US20080234194A1 US12/052,672 US5267208A US2008234194A1 US 20080234194 A1 US20080234194 A1 US 20080234194A1 US 5267208 A US5267208 A US 5267208A US 2008234194 A1 US2008234194 A1 US 2008234194A1
Authority
US
United States
Prior art keywords
vegf
skin
administered
collagen
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/052,672
Other languages
English (en)
Inventor
Harold Brem
Marjana Tomic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
Harold Brem
Marjana Tomic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harold Brem, Marjana Tomic filed Critical Harold Brem
Priority to US12/052,672 priority Critical patent/US20080234194A1/en
Publication of US20080234194A1 publication Critical patent/US20080234194A1/en
Assigned to NEW YORK UNIVERSITY reassignment NEW YORK UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOMIC, MARJANA
Assigned to NEW YORK UNIVERSITY reassignment NEW YORK UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREM, HAROLD
Priority to US12/858,828 priority patent/US9168214B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Definitions

  • VEGF-A is a 45-kDa homodimeric glycoprotein with a diverse range of angiogenic activities. It exists in many isoforms with a common amino terminus that contains a signal sequence that allows the protein to be secreted.
  • the VEGF-A gene consists of 8 exons and undergoes alternative splicing to yield mature isoforms of 121, 165, 189, and 206 amino acids (Houck, Mol Endocrin, 5:1806-1814 (1991)).
  • some less commonly expressed variants have also been identified (VEGF 145 and VEGF 183 ) (Neufiled, et al., FASEB J., 13:9-22 (1999)).
  • Growth factor encoding nucleic acids can be placed within linear or circular molecules. They can be placed within autonomously replicating molecules or within molecules without replication sequences. They can be regulated by their own or by other regulatory sequences, as is known in the art. Nucleic acid constructs encoding growth factor may include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of the growth factor sequences in the cells.
  • transcriptional regulatory elements such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of the growth factor sequences in the cells.
  • naked nucleic acid molecules are used as gene delivery vehicles, for example, as described in WO 9011 1092 and U.S. Pat. No. 5,580,859.
  • gene delivery vehicles can be either DNA or RNA and, in certain embodiments, are linked to killed adenovirus. Curiel, et al., Hum. Gene. Ther., 3:147-154 (1992).
  • Other suitable vehicles include DNA-ligand (Wu, et al., J. Biol. Chem. 264:16985-16987 (1989)), lipid-DNA combinations (Feigner, et al., Proc. Natl. Acad. Sci.
  • bioadhesive polymers that may be used in such a delivery system formulation are mentioned in U.S. Pat. No. 4,615,697. Typically, these polymers would not be used in their salt form, because this would decrease their bioadhesive capability.
  • Such bioadhesive polymers may be prepared by conventional free radical polymerization techniques utilizing initiators such as benzoyl peroxide, azobisisobutyronitrile. Exemplary preparations of useful bioadhesives are provided in U.S. Pat. No. 4,615,697.
  • the composition can be varied to affect certain properties of the formulation. For example, the viscosity can be varied by varying the concentration of therapeutic agents and carriers, or by adding a polymer or gel former.
  • Liquid compositions can be administered from absorbent materials, such as a bandage, patch or sponge, or as a spray or aerosol (applied to the affected area using a pump-type or aerosol sprayer).
  • absorbent materials such as a bandage, patch or sponge
  • a spray or aerosol applied to the affected area using a pump-type or aerosol sprayer.
  • the use of a patch or bandage, into which the composition has been incorporated, is advantageous in that it the composition will be slowly and continuously released.
  • Providing the composition in the form of a solution which may initially be provided in a concentrated liquid form, or as a sterile dissolvable powder, for example, in a packet or syringe, requiring the addition of water, saline or other suitable diluents prior to use may be advantageous.
  • the dose range of viral particles is between 10 11 and 10 7 viral particles.
  • the recombinant protein is delivered in a dosage range of be 10-100 micrograms per square centimeter.
  • the C57BL/KsJ db/db mouse is a particularly useful model since it has been shown to be a clinically relevant model of impaired wound healing.
  • the animals exhibit several characteristics of adult onset diabetes, including obesity, insulin-resistant hyperglycemia and markedly delayed wound closure.
  • C57BL/KsJ-db/db mice, homozygous for the diabetes spontaneous mutation become identifiably obese around 3 to 4 weeks of age. Elevations of plasma insulin begin at 10 to 14 days and of blood sugar at 4 to 8 weeks.
  • VEGF stimulates fibroblast migration and proliferation. This contributes to anti-wrinkle effect. VEGF increases dermal thickness. This contributes to smooth appearance of the skin and reduction of wrinkles. VEGF stimulates collagen deposition. This has dual effect: it reduces wrinkles and functions as a filler. VEGF increases tensile strength of the skin. This contributes to reduction of wrinkles and increases elasticity. VEGF stimulates fibroblasts from elderly (anti-aging effect). VEGF can also be administered to the skin following dermal abrasion, for treating conditions wherein collagen stimulation, epidermal stimulation or fat deposition would be beneficial or for enhancing epidermal.
US12/052,672 2007-03-20 2008-03-20 Growth factor mediated cosmeceuticals and use thereof to enhance skin quality Abandoned US20080234194A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/052,672 US20080234194A1 (en) 2007-03-20 2008-03-20 Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US12/858,828 US9168214B2 (en) 2007-03-20 2010-08-18 Methods of increasing collagen formation and cellular migration in intact skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89594207P 2007-03-20 2007-03-20
US12/052,672 US20080234194A1 (en) 2007-03-20 2008-03-20 Growth factor mediated cosmeceuticals and use thereof to enhance skin quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/858,828 Continuation US9168214B2 (en) 2007-03-20 2010-08-18 Methods of increasing collagen formation and cellular migration in intact skin

Publications (1)

Publication Number Publication Date
US20080234194A1 true US20080234194A1 (en) 2008-09-25

Family

ID=39481234

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/052,672 Abandoned US20080234194A1 (en) 2007-03-20 2008-03-20 Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US12/858,828 Active 2029-09-27 US9168214B2 (en) 2007-03-20 2010-08-18 Methods of increasing collagen formation and cellular migration in intact skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/858,828 Active 2029-09-27 US9168214B2 (en) 2007-03-20 2010-08-18 Methods of increasing collagen formation and cellular migration in intact skin

Country Status (3)

Country Link
US (2) US20080234194A1 (fr)
EP (1) EP2136778A2 (fr)
WO (1) WO2008116111A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191156A1 (en) * 2007-03-20 2009-07-30 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US20120189687A1 (en) * 2010-12-27 2012-07-26 Benjamin Johnson Compositions and Methods for Topical Application of Growth Factors and Cytokines
US8642655B2 (en) 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
US9132202B2 (en) * 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US10405795B1 (en) 2013-03-15 2019-09-10 The Procter & Gamble Company Methods of classifying periorbital dyschromia and systems therefor
CN114558114A (zh) * 2022-03-31 2022-05-31 温州医科大学 治疗压疮的乳剂型喷雾剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1394690B1 (it) * 2008-10-23 2012-07-13 Carli De Metodo di trattamento dermocosmetico della cute mediante applicazione di composizioni contenenti ngf.
US20120116295A1 (en) * 2010-11-10 2012-05-10 Pangaea Laboratories Ltd Topical Growth Factor Application Utilising a Microneedle Array
WO2015063613A2 (fr) 2013-11-01 2015-05-07 Spherium Biomed S.L. Corps d'inclusion pour administration transdermique d'agents thérapeutiques et cosmétiques
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
US4140122A (en) * 1976-06-11 1979-02-20 Siemens Aktiengesellschaft Implantable dosing device
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4603146A (en) * 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US4615697A (en) * 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4877805A (en) * 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5618544A (en) * 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US5639480A (en) * 1989-07-07 1997-06-17 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030235580A1 (en) * 2002-06-24 2003-12-25 Fen Zhang Amniotic membrane mediated delivery of bioactive molecules
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
US20040191278A1 (en) * 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US20090191156A1 (en) * 2007-03-20 2009-07-30 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
AU5001793A (en) * 1992-08-12 1994-03-15 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6773881B2 (en) * 2000-03-31 2004-08-10 The General Hospital Corporation Methods of modulating hair growth
JP2004534049A (ja) * 2001-06-07 2004-11-11 スキンメディカ，インコーポレーテッド 条件細胞培養培地とその用途
JP2003081866A (ja) * 2001-09-13 2003-03-19 Yasuhiko Tabata 細胞成長因子蛋白質を含む育毛用ハイドロゲル
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
KR100614903B1 (ko) * 2004-08-06 2006-08-25 테고사이언스 (주) 케라티노사이트 및/또는 섬유아세포를 함유하는 화장용조성물

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
US4140122A (en) * 1976-06-11 1979-02-20 Siemens Aktiengesellschaft Implantable dosing device
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4615697A (en) * 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4603146A (en) * 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4877805A (en) * 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5639480A (en) * 1989-07-07 1997-06-17 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5618544A (en) * 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030235580A1 (en) * 2002-06-24 2003-12-25 Fen Zhang Amniotic membrane mediated delivery of bioactive molecules
US20040191278A1 (en) * 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US20090191156A1 (en) * 2007-03-20 2009-07-30 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191156A1 (en) * 2007-03-20 2009-07-30 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
US9132202B2 (en) * 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US20120189687A1 (en) * 2010-12-27 2012-07-26 Benjamin Johnson Compositions and Methods for Topical Application of Growth Factors and Cytokines
US8642655B2 (en) 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
US10405795B1 (en) 2013-03-15 2019-09-10 The Procter & Gamble Company Methods of classifying periorbital dyschromia and systems therefor
CN114558114A (zh) * 2022-03-31 2022-05-31 温州医科大学 治疗压疮的乳剂型喷雾剂

Also Published As

Publication number Publication date
WO2008116111A2 (fr) 2008-09-25
US20100310517A1 (en) 2010-12-09
EP2136778A2 (fr) 2009-12-30
US9168214B2 (en) 2015-10-27
WO2008116111A3 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
US9168214B2 (en) Methods of increasing collagen formation and cellular migration in intact skin
US8673859B2 (en) GM-CSF cosmeceutical compositions and methods of use thereof
Khavari et al. Cutaneous gene transfer for skin and systemic diseases
Geusens et al. Lipid-mediated gene delivery to the skin
US9132202B2 (en) Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
Reish et al. Scar treatments: preclinical and clinical studies
US20080119433A1 (en) Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US20090186805A1 (en) Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
CN104363963A (zh) 局部皮肤制剂及皮肤个体化处理的方法
JP6369783B2 (ja) 加水分解フィブロインを含む軟膏及びその製造方法
WO2005060536A2 (fr) Technique de silençage genique mediee par si-rna en vue d'inhiber la tyrosinase et reduire la pigmentation
JP2006516649A (ja) 局所適用による化粧剤の送達方法
Liu et al. Liposome‐mediated transfer of vascular endothelial growth factor cDNA augments survival of random‐pattern skin flaps in the rat
EP3661540A1 (fr) Traitement d'états hypotrophiques cutanés locaux
US20100322998A1 (en) Skin ulcer preventive curative agent containing human recombinant hgf
KR102233647B1 (ko) 피부 재생 또는 상처 치료용 펩타이드 aec1d 및 이의 용도
EP1061942A1 (fr) Composition topique contenant un facteur de croissance epidermique d'origine humaine
CA3235725A1 (fr) Formulations de tensioactifs biologiques a utiliser dans le traitement de la peau et de plaies
CA2492331A1 (fr) Utilisation d'inhibiteurs de convertase dans le traitement de fibrose et de cicatrisation
CA3080179A1 (fr) Enzymes de reparation de l'adn ciblant le noyau et procedes d'utilisation
EP2968462B1 (fr) Procédés favorisant la cicatrisation des plaies et la croissance des poils
Pfützner et al. Advances in skin gene therapy
Proietti et al. Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma
KR102233646B1 (ko) 피부 재생 또는 상처 치료용 펩타이드 aes11-1 및 이의 용도
JP2024047895A (ja) 真皮細胞外マトリックス産生促進剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEW YORK UNIVERSITY,NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOMIC, MARJANA;REEL/FRAME:023969/0283

Effective date: 20091002

Owner name: NEW YORK UNIVERSITY,NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BREM, HAROLD;REEL/FRAME:023969/0303

Effective date: 20100130

Owner name: NEW YORK UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BREM, HAROLD;REEL/FRAME:023969/0303

Effective date: 20100130

Owner name: NEW YORK UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOMIC, MARJANA;REEL/FRAME:023969/0283

Effective date: 20091002

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION